Advertisement

Topical Corticosteroids: Pharmacology

Chapter

Abstract

Topical corticosteroids are widely used for inflammatory and hyperproliferative disorders in dermatology. Numerous topical corticosteroids with high local activity have been developed over the years, with a focus to develop drugs with high efficacy locally and minimum risk for adverse drug reactions. They are available in a number of formulations. Their therapeutic effects are a result of their anti-inflammatory, immunosuppressant, vasoconstrictive and anti-proliferative actions. An appropriate topical corticosteroid is selected on the basis of the dermatological condition to be treated, patient-related factors and the physicochemical properties of the drug. Their use is associated with mainly local adverse drug reactions, but prolonged use and/or use of high-potency topical corticosteroids may cause systemic effects.

Keywords

Topical corticosteroids Anti-inflammatory Anti-proliferative Potency 

References

  1. 1.
    Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101–2.CrossRefPubMedGoogle Scholar
  2. 2.
    Schimmer BP, Funder WH. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, editor. Pharmacological basis of therapeutics. 13th ed. New York, NY: McGraw-Hill. p. 1209–36.Google Scholar
  3. 3.
    Goldman L, Thomson RG, Trice ER. Cortisone acetate in skin disease: local effect in skin from topical applicants and local injections. AMA Arch Dermatol Syph. 1952;101-2(2):19.Google Scholar
  4. 4.
    Murray JR. The history of corticosteroids. Acta Derm Venereol. 1989;69(Suppl 151):4–6.Google Scholar
  5. 5.
    Katz M, Gans EH. Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and development—a process of “planned serendipity”. J Pharm Sci. 2008;97:2936–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Yohn JJ. WestonW.L. Topical glucocorticosteroids. Curr Probl Dermatol. 1990;2:31–63.CrossRefGoogle Scholar
  7. 7.
    Warner MR, Camisa C. Topical corticosteroids. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. 3rd ed. New York, NY: Elsevier Health. p. 487–504.Google Scholar
  8. 8.
    Brazzini B, Pimpinelli N. New and established corticosteroids in dermatology. Am J Clin Dermatol. 2002;3:47–58.CrossRefPubMedGoogle Scholar
  9. 9.
    Chrousos GP. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New York, NY: McGraw Hill; 2015. p. 680–95. www.accesspharmacy.com.Google Scholar
  10. 10.
    McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608–10.Google Scholar
  11. 11.
    Cornell RC. Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay. Int J Dermatol. 1992;31(Suppl 1):38–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121:63–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Drake L, Dinehart S, Farmer E, et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol. 1996;35:615–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Hepburn DJ, Aeling JL, Weston WL. A reappraisal of topical steroid potency. Pediatr Dermatol. 1996;13:239–45.CrossRefPubMedGoogle Scholar
  15. 15.
    Humbert P, Guichard A. The topical corticosteroid classification called into question: towards a new approach. Exp Dermatol. 2015;24:393–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Dumas KJ, Scholtz JR. The psoriasis bio-assay for topical corticosteroid activity. Acta Derm Venereol. 1972;52:43–8.PubMedGoogle Scholar
  17. 17.
    WHO model prescribing information: drugs used in skin diseases: Annex: Classification of topical corticosteroids. [Internet] [cited 13 Jan 2017]. Available from: http://apps.who.int/medicinedocs/en/d/Jh2918e/32.html#Jh2918e.32.1.
  18. 18.
    British National Formulary (BNF). 69th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; March 2015.Google Scholar
  19. 19.
    Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67(6):529–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Ponec M, Kempenaar JA, De Kloet ER. Corticoids and cultured human epidermal keratinocytes: specific intracellular binding and clinical efficacy. J Invest Dermatol. 1981;76:211–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Marks R, Barlow JW, Funder JW. Steroid-induced vasoconstriction:glucocorticoid antagonist studies. J Clin Endocrinol Metab. 1982;54:1075–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Mc Master A, Ray DW. Drug insight: selective agonists and antagonists of the glucocorticoid receptor. Nat Clin Pract Endocrinol Metab. 2008;4:91–101.CrossRefGoogle Scholar
  23. 23.
    Schacke H, Rehwinkel H, Asadullah K, Cato AC. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol. 2006;15:565–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50:3408–17.CrossRefPubMedGoogle Scholar
  25. 25.
    Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000;130:289–98.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Burkholder B. Topical corticosteroids: An update. Curr Probl Dermatol. 2000;12:222–5.CrossRefGoogle Scholar
  27. 27.
    Mori M, Pimpinelli N, Giannotti B. Topical corticosteroids and unwanted local effects. Improving the benefit/risk ratio. Drug Saf. 1994;10:406–12.CrossRefPubMedGoogle Scholar
  28. 28.
    Ahluwalia A. Topical glucocorticoids and the skin-mechanisms of action: an update. Mediat Inflamm. 1998;7:183–93.CrossRefGoogle Scholar
  29. 29.
    Buttgereit F, Saag KG, Cutolo M, Silva JAP, Bijlsma JWJ. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol. 2005;34:14–21.CrossRefPubMedGoogle Scholar
  30. 30.
    Altura BM. Role of glucocorticosteroids in local regulation of blood flow. Am J Phys. 1966;211:1393.Google Scholar
  31. 31.
    Hein R, Krieg T. Effects of corticosteroids on human fibroblasts in-vitro. In: Chrostophers E, Schopf E, Kligman AM, et al., editors. Topical corticosteroid therapy: a novel approach to safer drugs. New York, NY: Raven Press; 1988. p. 57–65.Google Scholar
  32. 32.
    Robertson DB, Maibach HI. Dermatologic pharmacology. In: Katzung BG, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New Delhi: McGraw Hill; 2015. p. 1033–51.Google Scholar
  33. 33.
    Lee NP, Ariola ER. Topical corticosteroids: back to basics. West J Med. 1999;171:351–3.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Ayres PJ, Hooper G. Assessment of the skin penetration properties of different carrier vehicles for topically applied cortisol. Br J Dermatol. 1978;307-17(5):99.Google Scholar
  35. 35.
    Fang JY, Leu YL, Wang YY, Tsai YH. In vitro topical application and in vivo pharmacodynamic evaluation of Nonivamide hydrogels using Wistar rat as an animal model. Eur J Pharm Sci. 2002;15:417–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Senyigit T, Ozer O. Corticosteroids for skin delivery: challenges and new formulation opportunities. Cited on 30 Jan 2017. Available from http://www.intechopen.com/books/references/glucocorticoids-new-recognition-of-our-familiar-friend/corticosteroids-for-skin-delivery-challenges-and-new-formulation-opportunities.
  37. 37.
    Hill CJH, Rostenberg A. Adverse effects from topical steroids. Cutis. 1978;21:624–8.PubMedGoogle Scholar
  38. 38.
    Lubach D, Bensmann A, Bonemann U. Steroid-induced dermal atrophy: investigations on discontinuous application. Dermatologica. 1989;179:67–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Valencia IC, Kerdel FA. Topical corticosteroids. In: Fitzpatrick’s dermatology in general medicine. 8th ed. New York, NY: McGraw Hill. p. 2659–64.Google Scholar
  40. 40.
    Correale CE, Walker C, Murphy L, Craig TJ. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician. 1999;60:1199–210.Google Scholar
  41. 41.
    Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol. 2002;146:351–64.CrossRefPubMedGoogle Scholar
  42. 42.
    Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15.CrossRefPubMedGoogle Scholar
  43. 43.
    Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5:416–25.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Chi C, Wang S, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;(10):CD007346. doi: 10.1002/14651858.CD007346.pub3.
  45. 45.
    Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275:71–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of PharmacologyChristian Medical College-LudhianaLudhianaIndia
  2. 2.Department of PharmacologyBurdwan Medical CollegeBurdwanIndia

Personalised recommendations